
|Articles|May 1, 2002
Immunogenicity of alefacept seen as minimal
New Orleans - Following treatment with IV- or IM-administered alefacept (Amevive), more than 1,000 patients with chronic plaque psoriasis showed insignificant levels of drug-related antibody.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Transformative Advances This Year and Beyond
2
FDA Proposes Expansion of US Sunscreen Ingredient Standards with Bemotrizinol
3
"PDE4 Inhibitor-Responsive Dermatoses": A Modern Framework for Managing Inflammatory Skin Conditions
4
Meta-analysis Confirms Benefits of Roflumilast 0.3% Cream for PsO
5


















